ONK is also developing ONKT104, a dual-targeted CAR-NK product targeting CLEC12A (also known as CLL-1) utilising a humanised ScFv. CLEC12A is strongly expressed by blasts in the majority of acute ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback